2019 Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets

1
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019 byGBI Research

• Explore all reports for Life Science market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces

2
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019

• Summary
• GBI Research, the leading business intelligence
  provider, has released its latest
  research,Pancreatic Adenocarcinoma Therapeutics
  in Major Developed Markets to 2019 Early Stage
  Pipeline Shows Diversity of Novel Targets though
  Commercial Impact Remains Distant, which
  provides in-depth analysis of pancreatic
  adenocarcinoma market within the eight major
  developed markets of the US, UK, France, Germany,
  Italy, Spain, Japan and Canada. The sreport
  provides an estimation of the market size for
  2012, along with market forecasts to 2019. It
  also covers disease epidemiology, treatment
  algorithms, treatment patterns, in-depth analysis
  of the pipeline, and deal analysis.
• The global pancreatic adenocarcinoma therapeutics
  market is expected to grow from approximately
  856m in 2012 to 1.2 billion in 2019, with
  growth driven by small changes in multiple
  factors. These include the impact of the drugs
  approved in the forecast period, but also the
  increase in the prevalence of the disease and
  minor improvements in diagnostics that result in
  more patients being eligible for pharmacological.

3
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019

• Scope
• A brief introduction to pancreatic
  adenocarcinoma, including the diseases
  pathogenesis, risk factors, diagnosis, staging
  and treatment algorithms for each stage.
• In-depth analysis of drugs available for the
  treatment of pancreatic adenocarcinoma, including
  analyses of their safety, efficacy, treatment
  patterns and strengths/weaknesses. Includes a
  heat map comparing the drugs in terms of safety
  and efficacy.
• Comprehensive review of the pipeline for
  pancreatic adenocarcinoma therapies, including
  individual analysis of a number of late-stage
  pipeline drugs that are likely to enter the
  market in the forecast period. The pipeline is
  analyzed on the basis of phase distribution,
  molecule types and molecular targets, program
  type.

4
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019

• Additional in-depth analysis of pipeline drug
  clinical trials by phase, molecule type, trial
  size, trial duration and program failure rate
  analyses for each molecule type and mechanism of
  action.
• Multi-scenario forecast data of the market to
  2019, taking into account how it will be affected
  by the introduction of new drugs, the expiry of
  key patents on current drugs and the changes in
  disease epidemiology across the key developed
  markets including the US, Japan, Germany, the UK,
  France, Italy and Spain.
• Discussion of the drivers and barriers for market
  growth.
• Discussion of the licensing and co-development
  deals landscape in pancreatic adenocarcinoma,
  Includes an analysis of licensing deals by stage
  of development, molecule type and mechanism of
  action. Also includes an analysis of both
  licensing and co-development deals by year and
  value and network maps of licensing and
  co-development deals.
• Buy a copy of this report by GBI Research _at_
  http//www.rnrmarketresearch.com/contacts/purchase
  ?rname168412 .

5
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019

• Reasons to buy
• Understand the vast scope and diversity of the
  pipeline, including which molecule types and
  mechanisms of action are prominent.
• Observe the trends in clinical trial duration and
  size amongst clinical Phases, between molecule
  types and mechanisms of action, and use the
  clinical trial failure rate analysis to assess
  the risk profiles of current and/or future
  developmental programs for pancreatic
  adenocarcinoma therapeutics.
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  on the pancreatic adenocarcinoma therapeutics
  market.
•  Complete report spread across 122 pages _at_
  http//www.rnrmarketresearch.com/pancreatic-adenoc
  arcinoma-therapeutics-in-major-developed-markets-t
  o-2019-early-stage-pipeline-shows-diversity-of-nov
  el-targets-though-commercial-impact-remains-distan
  t-market-report.html .

6
Pancreatic Adenocarcinoma Therapeutics in Major
Developed Markets to 2019

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.